Anti-tumour necrosis factor therapy in Crohn's disease: where are we now?
作者信息
van Deventer S J H
机构信息
Department of Experimental Medicine, Academic Medical Centre, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.
出版信息
Gut. 2002 Sep;51(3):362-3. doi: 10.1136/gut.51.3.362.
Abstract
摘要
相似文献
1
Anti-tumour necrosis factor therapy in Crohn's disease: where are we now?
Gut. 2002 Sep;51(3):362-3. doi: 10.1136/gut.51.3.362.
2
Anti-TNF therapy for Crohn's disease: a perspective (infliximab is not the drug we have been waiting for).
Inflamm Bowel Dis. 2000 May;6(2):137-9. doi: 10.1097/00054725-200005000-00011.
3
Exacerbation of Mycobacterium tuberculosis enteritis masquerading as Crohn's disease after treatment with a tumor necrosis factor-alpha inhibitor.
Am J Med. 2002 Jan;112(1):67-9. doi: 10.1016/s0002-9343(01)01035-x.
4
Successful use of adalimumab (Humira) for Crohn's disease in pregnancy.
Inflamm Bowel Dis. 2006 Aug;12(8):827-8. doi: 10.1097/00054725-200608000-00020.
5
Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy.
Gut. 2005 Oct;54(10):1360-2. doi: 10.1136/gut.2005.076034. Epub 2005 Aug 19.
6
New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease.
Rev Gastroenterol Disord. 2005 Winter;5(1):10-8.
7
Severe Listeria meningoencephalitis in an infliximab-treated patient with Crohn's disease.
Inflamm Bowel Dis. 2008 Mar;14(3):429-31. doi: 10.1002/ibd.20286.
8
Pericarditis as a complication of infliximab therapy in Crohn's disease.
Inflamm Bowel Dis. 2008 Mar;14(3):428-9. doi: 10.1002/ibd.20270.
9
Safe use of infliximab for the treatment of fistulizing Crohn's disease during pregnancy within 3 months of conception.
Inflamm Bowel Dis. 2008 Mar;14(3):435-6. doi: 10.1002/ibd.20319.
10
Infliximab treatment for Crohn's disease.
Postgrad Med J. 2001 Jul;77(909):436-40. doi: 10.1136/pmj.77.909.436.
引用本文的文献
1
Modulation of Intestinal Epithelial Permeability by Plasma from Patients with Crohn's Disease in a Three-dimensional Cell Culture Model.
Sci Rep. 2019 Feb 14;9(1):2030. doi: 10.1038/s41598-018-38322-8.
2
The long-term outcome of anti-TNF alpha therapy in perianal Crohn's disease.
Tech Coloproctol. 2017 Feb;21(2):119-124. doi: 10.1007/s10151-016-1578-4. Epub 2017 Jan 9.
本文引用的文献
1
Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis.
Am J Gastroenterol. 2004 Dec;99(12):2385-92. doi: 10.1111/j.1572-0241.2004.30186.x.
2
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.
Gut. 2002 Feb;50(2):206-11. doi: 10.1136/gut.50.2.206.
3
Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway.
Gastroenterology. 2001 Nov;121(5):1145-57. doi: 10.1053/gast.2001.28702.
4
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.
N Engl J Med. 2001 Oct 11;345(15):1098-104. doi: 10.1056/NEJMoa011110.
5
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.
Gastroenterology. 2001 May;120(6):1330-8. doi: 10.1053/gast.2001.24042.
6
Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance.
J Immunol. 1999 Jul 15;163(2):1081-90.
7
Infliximab for the treatment of fistulas in patients with Crohn's disease.
N Engl J Med. 1999 May 6;340(18):1398-405. doi: 10.1056/NEJM199905063401804.
8
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
N Engl J Med. 1997 Oct 9;337(15):1029-35. doi: 10.1056/NEJM199710093371502.
9
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
Lancet. 1997 Aug 2;350(9074):309-18. doi: 10.1016/S0140-6736(97)01300-7.
10
Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease.
Lancet. 1997 Feb 22;349(9051):521-4. doi: 10.1016/s0140-6736(97)80083-9.
Zotero 插件